A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally three times a week to patients with advanced cancer [abstract 341] - Dumez,H.; Hoekstra,R.; Eskens,F. (Proc Am Soc Clin Oncol, 2002)